EMC2 Statement on the recent social protests and racial injustice

To members of the Einsteinium Community:

We are deeply saddened as we have recently witnessed the horrific events around the deaths of George Floyd in Minnesota, Ahmaud Arbery in Georgia and Breonna Taylor in Kentucky to name a few. The Einsteinium Foundation joins in arms with others that oppose racial oppression and actively participate in efforts towards racial equity. Our foundation was built with the idea that an open society and the world together, regardless of race, ethnicity, or socio-economic background can accomplish anything. As a nonprofit organization founded to support scientific research through the blockchain The Einsteinium Foundation promotes critical thinking and peaceful and purposeful activism against injustice. We join with leaders and others across the globe in condemning violence towards peaceful protestors, and the deep-rooted racism towards people of color.

A number of resources have been made available online to support the ongoing efforts of those actively involved in the protests. If you are in a position to do so, please consider making a donation to these worthy organizations.

Through our collective action we will overcome these difficult times.

Leadership of The Einsteinium Foundation

About the Einsteinium Foundation: The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Press contact: Alexander Lucaci, Alexander.Lucaci@Emc2.Foundation

Community update on The Einsteinium Foundation progress for the release of MIL

May 2020

To the Einsteinium Community,

Plans

We remain committed to the release of MIL as it is the clear path forward for Einsteinium to support its overarching mission. This includes our recent initiatives to support the ongoing medical response to COVID-19 which can been seen in our recent blog posts.

This update describes the progress made by The Einsteinium Foundation thus far in the undertaken project as well as the remaining tasks. An overall assessment of the project is provided as well as a forecast for its completion. In an effort to determine the best strategy for completion, the current leadership has considered multiple options which includes converting the current project to open source. Additionally, we may initiate a code completion bounty. This would be in line with our core values of transparency and openness. 

Progress

Overall, the project is on track for completion. Currently our group is searching for additional talent and financial support from the Ethereum community in order to speed up its progress. We intend to resolve some of the technical issues that have been encountered and are typical of modern blockchain development. Additionally, we will present the major gaps and consequences of contemporary governments support for science and how our solutions (including MIL) will improve the funding environment and transparency.

Summary

During this project we have encountered some minor problems. 

The newly restructured management are working diligently to solve these issues and keep our community in the loop. Considering our previous success in remedying technical situations, our group is fit for completing the MIL release in the near future.

We are looking to add to our ranks

We are looking to recruit persons that are interested and capable of supporting the ongoing mission of EMC2. Of paramount importance is the organization of human capital willing to work on long term problems. If you are interested, please fill out the short form on our Careers page below:

Stewards of The Einsteinium Foundation

About the Einsteinium Foundation: The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Press contact: Alexander Lucaci, Alexander.Lucaci@Emc2.Foundation

Donate Today!: Your support is crucial to the continued efforts of EMC2 to fund scientific research for the benefit of humanity. If you’re able to, we’d love it if you could make a direct donation to help us achieve our mission.

(EMC2 Foundation) Bitcoin Wallet

  • 14NK9PF1MujjbjdJeRbALhaNeJ66e3TFRV (Created for this initiative)

(EMC2 Foundation) EMC2 Wallet

  • ESWqLTVVgJhqHYD2sa3dWsbS7jqRah7TS1

Subscribe to The Einsteinium Foundations email list to get up to date information.

Contact us via:

2020 - Annual Einsteinium Award.

Scientific research is a long-term investment in our future, and the future of our planet. The Einsteinium Foundation is proud to announce an Open Call for applications for the second annual Einsteinium Award.

We are interested in supporting a broad range of scientific work. Therefore, applicants must be from a University or Graduate studies program. We are seeking top-level research from Students, Postdocs, and Professors from all over the world.

The prize for 2020’s award will be 100,000 EMC2 to be given as a grant to the most worthy scientific project. Apply today at:

The Einsteinium Foundation (EMC2) announces COVID-19 response funding to Elemeno Health

May 2020 

The Einsteinium Foundation, a non-profit organization (NPO), and a community-driven cryptocurrency that leverages blockchain technology to raise capital for scientific research today announces it has signed an agreement to support the continuing response to the ongoing COVID-19 outbreak. This represents the second significant action from The Einsteinium Foundation (25,000 EMC2) and demonstrates our ability to move quickly and decisively to support frontline workers during this crisis. Elemeno Health (https://www.elemenohealth.com/), located in Oakland, California is the recipient of this funding led by EMC2. The funding for this partnership will be applied directly to ongoing efforts to combat the COVID-19 virus SARS-CoV-2. Elemeno Health is “A cloud-based solution that drives frontline adoption of your best practices, through just-in-time support at the point of need, to deliver reliability, quality safety, at a lower cost.” CEO Dr. Arup Roy-Burman will be responsible for administration of the donation.

In addition, Elemeno Health is also running an equity crowd-funding campaign on Republic.co (a Startup investing platform). If you are interested, please visit and support their actions at: 

The Einsteinium Foundation (EMC2) is committed to the COVID-19 response. We are actively searching to fund innovation in the area of therapies, drugs, and vaccines related to the SARS-CoV-2 virus.

We are accepting applications via: https://www.emc2.foundation/covid-19-funding

Sincerely,

Leadership of The Einsteinium Foundation

About the Einsteinium Foundation

The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Donate Today!

Your support is crucial to the continued efforts of EMC2 to fund scientific research for the benefit of humanity. If you’re able to, we’d love it if you could make a direct donation to help us achieve our mission.

EMC2 Foundation - Bitcoin Wallet

  • 14NK9PF1MujjbjdJeRbALhaNeJ66e3TFRV 

EMC2 Foundation - EMC2 Wallet

  • ESWqLTVVgJhqHYD2sa3dWsbS7jqRah7TS1

Contact us via

Media contact

Alexander G. Lucaci

Alexander.Lucaci@Emc2.Foundation

Subscribe to The Einsteinium Foundations email list to get up to date information.

The Einsteinium Foundation (EMC2) announces COVID-19 response funding to Serim General Hospital

May 2020 - The Einsteinium Foundation, a non-profit organization (NPO), and a community-driven cryptocurrency that leverages blockchain technology to raise capital for scientific research today announces it has completed a direct donation to support the continuing response to the ongoing COVID-19 outbreak. This represents the first significant donation from The Einsteinium Foundation (125,000 EMC2) and demonstrates our ability to move quickly and decisively to support frontline workers during this crisis. Serim General Hospital, located in the Republic of Korea is the recipient of this funding led by EMC2. The funding for this partnership will be applied directly to ongoing efforts to combat the COVID-19 virus SARS-CoV-2. Serim General Hospital is the largest hospital in the Bupyeong District and is one of the governments designated COVID-19 hospitals. Hospital Director Dr Moon-Sool Yang will be responsible for administration of the donation.

The Einsteinium Foundation (EMC2) is committed to the COVID-19 response. We are actively searching to fund innovation in the area of therapies, drugs, and vaccines related to the SARS-CoV-2 virus.

About the Einsteinium Foundation

The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Donate Today: Your support is crucial to the continued efforts of EMC2 to fund scientific research for the benefit of humanity. If you’re able to, we’d love it if you could make a direct donation to help us achieve our mission.

EMC2 Foundation - Bitcoin Wallet

  • 14NK9PF1MujjbjdJeRbALhaNeJ66e3TFRV 

EMC2 Foundation - EMC2 Wallet

  • ESWqLTVVgJhqHYD2sa3dWsbS7jqRah7TS1

Contact us via

Website: https://www.emc2.foundation/

Twitter: @EMC2Foundation

Facebook: https://www.facebook.com/einsteiniumfoundation

Reddit: https://www.reddit.com/r/einsteinium/

Bitcointalk: BitcoinTalk: EMC2

Discord: Discord EMC2

Telegram: Telegram EMC2 Channel

Media contact

Alexander G. Lucaci

Alexander.Lucaci@Emc2.Foundation

Community update on the restructuring of The Einsteinium Foundation

April 2020

To the Einsteinium community,

The leadership and stewards of The Einsteinium Foundation have been monitoring and carrying out an examination of our leadership structure. The organizational structure has been efficient for the past few years. However, there have been some concerns about the organizational structure recently. Therefore, the Board of Directors aims to restructure The Einsteinium Foundation for the sustainable support of scientific research. We believe that this restructuring will preserve the ongoing mission and purpose of this organization.

The new organizational structure will be defined below.

  • Chairman: Alexander G Lucaci

  • Board Member and CFO: Jonathan Lauziere

  • Board Member and CTO: Vladan Bozilovic

  • Board Member: Ryan Wright

  • Head of Business Development: Malden Trifunovic

  • Head of Development in Korea: Jamie Min

We also engage with several Advisory roles which provide assistance to the EMC2 Foundation by offering innovative and dynamic perspectives. 

Thank you for your hard work and support as we continue to carry out our ongoing mission.

Leadership of The Einsteinium Foundation

Contact us via:

Website: https://www.emc2.foundation/

Twitter: @EMC2Foundation

Facebook: https://www.facebook.com/einsteiniumfoundation

Reddit: https://www.reddit.com/r/einsteinium/

Bitcointalk: BitcoinTalk: EMC2

Discord: Discord EMC2

Telegram: Telegram EMC2 Channel

Press contact: Alexander Lucaci, <Alexander.Lucaci@EMC2.Foundation>

About the Einsteinium Foundation: The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Donate Today: Your support is crucial to the continued efforts of EMC2 to fund scientific research for the benefit of humanity. If you’re able to, we’d love it if you could make a direct donation to help us achieve our mission.

(EMC2 Foundation) Bitcoin Wallet

  • 14NK9PF1MujjbjdJeRbALhaNeJ66e3TFRV

(EMC2 Foundation) EMC2 Wallet

  • ESWqLTVVgJhqHYD2sa3dWsbS7jqRah7TS1

The Einsteinium Foundation (EMC2) response to the ongoing COVID-19 outbreak

Our commitment.

The Einsteinium Foundation (EMC2) is committed to helping with the response to the ongoing COVID-19 outbreak. We are actively looking to fund innovation in the area of therapies, drugs, and vaccines related to the SARS-CoV-2 virus. We urge members of the Einsteinium community actively involved in scientific work to reach out to us via email (projects@emc2.foundation) or the short form below. Additionally, for any member of the crypto community at large that believes in our mission and is looking to be involved in some manner, we have a short form below where you can sign up.

For companies and academic scientific researchers: We are looking to support an array of scientific work related to COVID-19 disease. Examples of this include diagnostics, therapeutics, or modeling for epidemiological characteristics. We hope to accommodate applications for fast-track funding via the short form below: 

For members of the community that want to participate in the response: We are looking to recruit anyone that is interested and capable of supporting the ongoing mission of EMC2. Of paramount importance is the organization of human capital willing to take on this difficult problem in an emergency. If you are interested, please fill out the short form on our Careers page below:

  In these unprecedented times, we hope for your safety and that of your families. Please stay home and help to flatten the curve. The decisions and actions we take today can impact the future spread or mitigation of this virus. From past outbreaks, we know that with combined human effort we will make it through this to more prosperous times. 

Sincerely,

Leadership of The Einsteinium Foundation

Contact us via:

Website: https://www.emc2.foundation/

Twitter: @EMC2Foundation

Facebook: https://www.facebook.com/einsteiniumfoundation

Reddit: https://www.reddit.com/r/einsteinium/

Bitcointalk: BitcoinTalk: EMC2

Discord: Discord EMC2

Telegram: Telegram EMC2 Channel

Press contact: Alexander Lucaci, Alexander.Lucaci@Emc2.Foundation

About the Einsteinium Foundation: The Einsteinium Foundation is a non-profit organization (NPO), and the world's first NPO to be backed by cryptocurrency. The defining characteristics of The Einsteinium Foundation is its ongoing commitment to research and charitable missions throughout the world, and to the safeguarding, maintenance, and development of Einsteinium, an international digital currency built on a secure, decentralized open ledger, or blockchain.

Donate Today: Your support is crucial to the continued efforts of EMC2 to fund scientific research for the benefit of humanity. If you’re able to, we’d love it if you could make a direct donation to help us achieve our mission.

(EMC2 Foundation) Bitcoin Wallet

  • 14NK9PF1MujjbjdJeRbALhaNeJ66e3TFRV (Created for this initiative)

(EMC2 Foundation) EMC2 Wallet

  • ESWqLTVVgJhqHYD2sa3dWsbS7jqRah7TS1

US and Canadian Securities Regulators Coordinate ICO Probe in ‘Operation Cryptosweep’

 

US and Canadian state and provincial securities regulators have opened probes into potentially fraudulent crypto investment programs in what has been dubbed “Operation Cryptosweep”, according to a press release May 21. The latest crackdown on suspicious crypto investment products is reportedly the largest such coordinated investigation by state and provincial officials.

Regulators from across 40 jurisdictions coordinated by the North American Securities Administrators Association (NASAA) have initiated up to 70 investigations, with more to come in the following weeks. Securities regulators have reportedly warned as many as 35 companies about violations of state securities laws with some cases resulting in cease-and-desist actions.

NASAA, which released a warning for Main Street investors regarding the risks associated with crypto and ICOs early this year, said the probe is focusing on suspicious cases of initial coin offerings (ICOs).

According to the Washington Post, investigators discovered about 30,000 crypto-related domain names in recent weeks, most of which were registered last year when the Bitcoin (BTC) price reached its all-time-high of around $20,000.

Alleged scams have reportedly used fake addresses, flashy marketing materials, and guarantees of up to a 4 percent daily interest rate, while failing to report the potential risks of crypto-investments. Some fraudulent ICOs even used fake celebrity photos to endorse their product.

The president of NASAA Joseph Borg stated that regulators do their best to stay one step ahead of potential security violations, noting that not every ICO or cryptocurrency investment is fraudulent.

"We’re putting ourselves in the shoes of investors. We’re seeing what’s being promoted to investors. And then we’re taking the next step and then we’re finding out whether they’re complying with securities laws."

Founded in 1919, the NASAA is an association of state and provincial-level securities regulators in the US, Mexico, and Canada. Through the association, state securities regulators can coordinate and take part in “multi-state enforcement actions,” as well as share information.

Earlier in May, the US Securities and Exchange Commission (SEC) launched a fake initial coin offering website to increase awareness of the typical warning signs of scam ICOs and to promote investor education.

Original text is taken form https://cointelegraph.com/news/us-and-canadian-securities-regulators-coordinate-ico-probe-in-operation-cryptosweep

Global Cell Med is on a Mission to heal the World

Global Cell Med is not a household name, but someday that could change. The organization, based out of the Bahamas, under the direction of Dr. Alejandro Mesples has been working on a procedure to treat Diabetes Type One, a global epidemic currently affecting more than 30 million adults and children in the US alone.

We are pleased to be sharing their important work and look forward to helping them reach their goals once we launch our Einsteinium Accelerator later this summer.

To learn more about the organization and their cutting edge procedure, you can read their project summary here:

INTRODUCTION

EXHIBIT A PROJECT SUMMARY GLOBAL CELL MED USA

 

Global Cell Med USA is a medical biotechnology company that is involved in the treatment of type 1 diabetes in humans. Specifically focused on the diabetes treatment protocol created by Alejandro Mesples, M.D., an internationally recognized researcher in regenerative medicine who specializes in the treatment of diabetes and vascular diseases.

WORLDWIDE EPIDEMIC

Diabetes is a growing epidemic and it is global. In the United States alone, 30.6 million children and adults (10-13% of the population) have diabetes. Currently, one in three newborns in the U.S. are projected to be diagnosed with diabetes during their lifetime. The World Health Organization claims diabetes is an epidemic without control. It is one of the leading causes of mortality in the world, causing over 6 million deaths annually. Diabetes is the 7th leading cause of death in the US.

Current treatment for type 1 diabetes does not have any healing outcomes and is very disruptive to quality of life. Diabetes can cause vascular disease that causes cerebral infarcts, heart disease, blindness, kidney failure that can lead to dialysis, and neropathy of the lower limbs that can lead to amputation.

It also creates massive costs and expenditures for individuals and healthcare systems. In the U.S., the total annual economic cost of diabetes in 2015 was an estimated $245 billion.

In the time it takes to read this summary, 161 diabetics have died and 1200 have lost a limb.

Type 1 Diabetes

The human body has a complex system to convert digested food into energy, which is necessary for survival. The body’s digestive system converts digested food into glucose, often referred to as blood sugar, and it is deposited into the blood stream. The glucose in the blood stream is taken into cells where it is converted to glucagon, the body’s energy source. Insulin is the key enzyme in this process and it is made primarily in the islet cells within the pancreas. Type 1 diabetics have none or very small amounts of naturally produced insulin in their bodies. They cannot convert blood sugar into glucagon so they have no way to produce life supporting energy.

Unfortunately, type 1 diabetics are predisposed to diabetes. It is a generic disease so one cannot be naturally infected with the disease. Generally some kind of trigger, either internal and/or external, signals the diabetic’s autoimmune system to treat their islet cells in their pancreas as an antigen or foreign invader to the body. The autoimmune system then destroys the insulin producing islet cells and the process for creating energy for the body.

The only current effective strategy for treating type 1 diabetics and preventing death is to inject diabetics with insulin throughout the day on a predetermined schedule. Insulin treatment is invasive, complicated to use, and very expensive.

SOLUTION
Dr. Alejandro Mesples’ Type 1 Diabetes Treatment Protocol

The therapy strategy invented by Dr. Alejandro Mesples is patent pending. It is based on the utilization of a diabetic’s own stem cells within their bone marrow. A patient’s bone marrow is stimulated using a drug called Filgrastim and then the stem cells are aspirated from the iliac crest bone. Those bone marrow stem cells undergo another regime of preparation before they are reintroduced back into the patient. The aspirated and prepared bone marrow stem cells are then transplanted into the patient via intravenous injection – an ambulatory procedure. Dr. Mesples’ treatment does not use autoimmune suppressant drugs or cell culture.

Three governments, Argentina, Chile, and Bahamas, have approved this therapy. The University of Miami Medical Stem Cell Division completed an Independent Review Board Opinion on the efficacy of the treatment protocol, approving the treatment as a consultant for the Bahamian National Stem Cell Committee. Dr. Mesples’ treatment protocol has been peer reviewed by international medical journals and sponsored by one of the largest stem cell researchers in the world, Beike Biotechnology.

Dr. Mesples’ treatment protocol of transplanting autologous bone marrow stem cells, without immuno suppression, into chronic type 1 diabetic patients, is a treatment that drastically improves the health and quality of life of the diabetic patient. This treatment manages to recover the function of the injured pancreatic islet cells and increase the production of insulin in 75% of patients within 4 months after treatment. Allowing treated patients to achieve metabolic stabilization, requiring lower doses of insulin or becoming insulin free for 3 to 5 years. The treatment does not cause lesions in the bone marrow, which recovers quickly after transplantation, so the treatment can be repeated as many times as necessary to continue or improve metabolic stabilization.

Currently, there is no approved diabetes treatment like this available in the US. Through his company Stem Cell Bahamas, Dr. Mesples is conducting a clinical trial at Doctors Hospital - Bahamas Medical Center in Nassau, The Bahamas. This trial is open to any type 1 diabetic and chronic type 2 diabetic worldwide.

The Science of Stem Cell Therapy

When a diabetic’s adult stem cells that have been treated using the Mesples’ process are injected into the diabetic, the treated stem cells are directed to the damaged pancreas using chemokines. The stem cells that migrate through the action of chemokines biologically reach the designated pancreas and secrete mediators. This action causes local stem cell activation, differentiation, and the damaged cells in the pancreas are transformed by the human body into healthy islet cells.

Stem cells are special cells in our body that can replicate and differentiate – meaning they can transform into a myriad of healthy functioning cells found in your body. Dr. Mesples’ treatment protocol uses a diabetic’s adult stem cells that already exist in their bone marrow are small protein molecules that act as chemattractants, leading the migration of treated stem cells to the damaged pancreas.

Through his research Dr. Mesples has confirmed that adult stem cells can provide a replacement source of cells to treat serious diseases. This ultimately means that virtually any disease that results in cellular and tissue destruction can potentially be replaced by adult stem cells.

History of Dr. Mesples Diabetes Treatment Protocol

Dr. Mesples research into diabetes treatment began in Argentina. There he created a diabetes treatment that involved infusing a diabetic’s own stem cells, collected from the diabetic’s bone marrow, into the pancreatic system to stimulate the regrowth of islet cells in the pancreas. The treatment was non invasive and did not utilize autoimmune suppressant drugs. In 2005 the Argentinian Government authorized Dr. Mesples to conduct clinical trials, using his new treatment protocol. The results were very promising. There were no adverse side effects or health events. The treatment was shown to improve blood glucose control, insulin secretion, reduce insulin injection requirements, and not require autoimmune suppressant drugs. The new treatment protocol showed a strong potential to become a primary or supplemental treatment for type 1 diabetes sufferers, improving their quality of life, avoiding complications of diabetes such as kidney failure, blindness, and lower limb neurological damage.

The results of the Argentinian clinical trials for Dr. Mesples new diabetes treatment protocol attracted the attention of the largest biotechnical company in China, Beike Biotechnology. Beike is a world leader in stem cell research and medical applications. Over the next decade Dr. Mesples conducted research and clinical trials in China, substantiating his original results and improving on the treatment process.

Dr. Mesples and his team at Stem Cell Bahamas have begun a clinical trial at the Bahamas Medial Clinic. The current trial was approved by the government’s National Stem Cell Committee and confirmed for efficacy via an Independent Review Board Opinion by the University of Miami Medical Stem Cell Division. (The Bahamas clinical trial is similar to a Phase 3 FDA trial in the US ) The trial is being conducted at the Bahamas Medical Center, owned by Doctor’s Hospital Health Systems of The Bahamas. Doctors Hospital is accredited by the Joint Commission International (JCI).

JCI is the international arm of the U.S.-based Joint Commission on the Accreditation of Healthcare Organizations (JCAHO); the same body that certifies more than 21,000 hospitals in the United States. Fewer than 850 hospitals outside of the United States have earned the accreditation and Doctors Hospital remains one of only two acute care hospitals in the Caribbean region to be recognized for its consistent adherence to international quality standards.

The new trial in the Bahamas will utilize a larger patient base and develop a standard protocol for the stem cell re-transplantation process. At the conclusion of the Bahamas’ clinical trial, Dr. Mesples will apply for a marketing permit from the Bahamian Government to begin selling his treatment to medical practitioners that treat diabetic patients from around the world.

Historical Clinical Trial Results for Dr. Mesples’ Treatment Protocol

Within the last three years, 3 meta-analyzes were published in medical journals concerning the transplantation of different types of cells and techniques to treat type 1 diabetics. This analysis included over 1500 patients from around the world (outside the US).

The meta-analyzes showed that adult hematopoietic stem cells are the ones that show the best results in terms of the peptide c elevation and the decrease in daily insulin use. Dr. Mesples came to these same conclusions in his research 10 years ago.

The complete clinical results of Dr. Mesples’ clinical trials are not provided here because they are lengthy and very technical. The complete research documentation (clinical results) provided to the Argentinian Government about Dr. Mesples’ initial clinical trials, research and clinical trial results with Beike Biotechnology, and similar information provided to the National Stem Cell Committee of the Bahamian Government is available to qualified recipients after signing a Non Disclosure Non Circumvention Agreement.

WHY IS DR. MESPLES’ DIABETES TREATMENT SO IMPORTANT IN THE UNITED STATES?

Medical research and treatment protocols of diseases in the United States are a multi billion dollar industry. By law all new drugs and medical treatments must be approved by the Food and Drug Administration (FDA). This process is arduous, can take 10 years or more, and is very expensive. The FDA approval process has become a typical government bureaucracy that is controlled by the largest drug companies, medical research facilities, and political philanthropic organizations through political persuasion. Although factions of the medical industrial complex have noble objectives to cure diseases, it rarely happens. Diabetes is a classic example.

A diabetic can live a long life with diabetes if they take insulin correctly and do a reasonable job of controlling their blood sugar levels. However, the longer a person has diabetes the probability of kidney failure, eye problems, and nerve damage to lower extremities increase significantly. This is the perfect disease for the medical industrial complex. Drug companies make billions selling insulin and blood sugar testing equipment. Philanthropic entities like the Juvenile Diabetes Research Foundation (JDRF) raise tens of millions of dollars a year from well meaning donors for diabetes research and then provide grants to medical research facilities to find a cure. JDRF has been doing that for over 30 years and are no closer to a cure than when they started. Medical research about diabetes is fragmented and old concepts are rarely challenged. When Global Cell Med USA contacted JDRF about discussing Dr. Mesples treatment protocol, they declined. There are no FDA approved medical treatments for diabetes using stem cells and no immuno suppression drugs available in the US market.

Dr.Mesples’ research in Argentina was not hampered by the bureaucracy and financial agendas inherent in the US. Thus he was able to create a treatment for diabetes using stem cells that does not require autoimmune suppressant drugs. Do to the successful results of Dr. Mesples’ previous clinical trials, Global Cell Med USA should be able to enter the FDA approval process as a mature Phase 3 stem cell treatment clinical trial, eliminating years of clinical trials and millions of dollars in expenses. As soon as the minimum number of patients are treated and the results approved by the FDA, Global Cell Med USA could have a treatment for diabetes on the market in the US in less than 2 years that is non invasive, economical, and effective.

Business Plan

Global Cell Med USA is an affiliated company of Stem Cell Bahamas, which desires to expand into the United States, the largest market for type 1 diabetes in North America with over 3 million diagnosed sufferers.

The objectives of Global Cell Med USA are:

  1. To help heal type 1 diabetics, utilizing Dr. Mesples’ diabetes treatment protocol in the United States.

  2. The first step is to obtain a New Investigative Drug Number (IND) from the US Food & Drug Administration and enter their approval process at Phase 3. This is the last clinical phase before the stem cell treatment is approved for mass marketing as a medical practice.

  3. The next step is to obtain an Independent Review Board Opinion (IBR) on the efficacy of Dr. Mesples’ treatment protocol for treating type 1 diabetics.

  4. Then Global Cell Med USA will be in a position to contract with hospitals and other diabetic treatment facilities to use Dr. Mesples’ treatment protocol, expanding its Phase 3 clinical trials for new stem cell treatments.

  5. Once the Phase 3 clinical trials results have been examined and approved by the FDA, Global Cell Med USA will obtain a permit to market Dr. Mesples’ treatment protocol to qualified medical practitioners that treat diabetes in the US.

Global Cell Med USA intents to present to the FDA the clinical trial data from Argentina, China, and Bahamas and use that data to get credit for completing Phases 1 and 2 in the FDA’s new stem cell treatment approval process. If approved the US clinical trial will begin as a final Phase 3 trial.

Once Global Cell Med USA has obtained an IND from the FDA, it will partner with medical providers in the US that qualify to conduct clinical trials for type 1 diabetes treatment. These initial partnerships will be located in population centers so they can service as many type 1 diabetics as possible.

Global Cell Med USA will use the clinical trial results from the Bahamas in combination with the results from Phase 3 clinical trials in the US and partition the FDA to shorten the number of patient requirements for a Phase 3 clinical trial. If successful Global Cell Med USA will substantially shorten the timeline for applying for a marketing permit to sell Dr. Mesples stem cell treatment to a large number medical practitioners that treat diabetics. This would be the first a non evasive, economical, and effective treatment for type 1 diabetes that can help heal millions of type 1 diabetics within the United States.